Survival in unresectable AJCC stage i and II HCC and the effect of DEB-TACE

SEER versus tertiary cancer center cohort study

Minzhi Xing, Nima Kokabi, Hasmukh Prajapati, Orrie Close, Johannes M. Ludwig, Hyun S. Kim

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Aim: To evaluate overall survival (OS) in unresectable American Joint Committee on Cancer (AJCC) stage I/II hepatocellular carcinoma (HCC) treated with drug-eluting-bead transarterial chemoembolization (DEB-TACE) versus best supportive care. Materials & methods: OS in consecutive patients with AJCC stage I/II unresectable HCC diagnosed in 2005-2010 who underwent DEB-TACE and similar patients from SEER with no surgery/radiation recommended/performed was evaluated. Results: Median OS from HCC diagnosis was 28.9 months (DEB-TACE) versus 10.0 months (SEER), p < 0.0001. Median OS was 36.3 months (DEB-TACE) versus 12.0 months (SEER) in AJCC I, and 27.9 months (DEB-TACE) versus 10.0 months (SEER) in AJCC II, p < 0.0001. Significant independent prognostic factors for OS were single primary tumor, no vascular invasion, normal α-fetoprotein and DEB-TACE. Conclusion: DEB-TACE in patients with unresectable AJCC stage I/II HCC was a significant independent prognostic factor for greater OS in a population-based study.

Original languageEnglish (US)
Pages (from-to)141-154
Number of pages14
JournalJournal of Comparative Effectiveness Research
Volume5
Issue number2
DOIs
StatePublished - Mar 1 2016

Fingerprint

Hepatocellular Carcinoma
Cohort Studies
Survival
Pharmaceutical Preparations
Neoplasms
Fetal Proteins
Blood Vessels
Radiation
Population

All Science Journal Classification (ASJC) codes

  • Health Policy

Cite this

Survival in unresectable AJCC stage i and II HCC and the effect of DEB-TACE : SEER versus tertiary cancer center cohort study. / Xing, Minzhi; Kokabi, Nima; Prajapati, Hasmukh; Close, Orrie; Ludwig, Johannes M.; Kim, Hyun S.

In: Journal of Comparative Effectiveness Research, Vol. 5, No. 2, 01.03.2016, p. 141-154.

Research output: Contribution to journalArticle

@article{8c1696da2fbc43cf9967594242bac38d,
title = "Survival in unresectable AJCC stage i and II HCC and the effect of DEB-TACE: SEER versus tertiary cancer center cohort study",
abstract = "Aim: To evaluate overall survival (OS) in unresectable American Joint Committee on Cancer (AJCC) stage I/II hepatocellular carcinoma (HCC) treated with drug-eluting-bead transarterial chemoembolization (DEB-TACE) versus best supportive care. Materials & methods: OS in consecutive patients with AJCC stage I/II unresectable HCC diagnosed in 2005-2010 who underwent DEB-TACE and similar patients from SEER with no surgery/radiation recommended/performed was evaluated. Results: Median OS from HCC diagnosis was 28.9 months (DEB-TACE) versus 10.0 months (SEER), p < 0.0001. Median OS was 36.3 months (DEB-TACE) versus 12.0 months (SEER) in AJCC I, and 27.9 months (DEB-TACE) versus 10.0 months (SEER) in AJCC II, p < 0.0001. Significant independent prognostic factors for OS were single primary tumor, no vascular invasion, normal α-fetoprotein and DEB-TACE. Conclusion: DEB-TACE in patients with unresectable AJCC stage I/II HCC was a significant independent prognostic factor for greater OS in a population-based study.",
author = "Minzhi Xing and Nima Kokabi and Hasmukh Prajapati and Orrie Close and Ludwig, {Johannes M.} and Kim, {Hyun S.}",
year = "2016",
month = "3",
day = "1",
doi = "10.2217/cer.15.54",
language = "English (US)",
volume = "5",
pages = "141--154",
journal = "Journal of Comparative Effectiveness Research",
issn = "2042-6305",
publisher = "Future Medicine Ltd.",
number = "2",

}

TY - JOUR

T1 - Survival in unresectable AJCC stage i and II HCC and the effect of DEB-TACE

T2 - SEER versus tertiary cancer center cohort study

AU - Xing, Minzhi

AU - Kokabi, Nima

AU - Prajapati, Hasmukh

AU - Close, Orrie

AU - Ludwig, Johannes M.

AU - Kim, Hyun S.

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Aim: To evaluate overall survival (OS) in unresectable American Joint Committee on Cancer (AJCC) stage I/II hepatocellular carcinoma (HCC) treated with drug-eluting-bead transarterial chemoembolization (DEB-TACE) versus best supportive care. Materials & methods: OS in consecutive patients with AJCC stage I/II unresectable HCC diagnosed in 2005-2010 who underwent DEB-TACE and similar patients from SEER with no surgery/radiation recommended/performed was evaluated. Results: Median OS from HCC diagnosis was 28.9 months (DEB-TACE) versus 10.0 months (SEER), p < 0.0001. Median OS was 36.3 months (DEB-TACE) versus 12.0 months (SEER) in AJCC I, and 27.9 months (DEB-TACE) versus 10.0 months (SEER) in AJCC II, p < 0.0001. Significant independent prognostic factors for OS were single primary tumor, no vascular invasion, normal α-fetoprotein and DEB-TACE. Conclusion: DEB-TACE in patients with unresectable AJCC stage I/II HCC was a significant independent prognostic factor for greater OS in a population-based study.

AB - Aim: To evaluate overall survival (OS) in unresectable American Joint Committee on Cancer (AJCC) stage I/II hepatocellular carcinoma (HCC) treated with drug-eluting-bead transarterial chemoembolization (DEB-TACE) versus best supportive care. Materials & methods: OS in consecutive patients with AJCC stage I/II unresectable HCC diagnosed in 2005-2010 who underwent DEB-TACE and similar patients from SEER with no surgery/radiation recommended/performed was evaluated. Results: Median OS from HCC diagnosis was 28.9 months (DEB-TACE) versus 10.0 months (SEER), p < 0.0001. Median OS was 36.3 months (DEB-TACE) versus 12.0 months (SEER) in AJCC I, and 27.9 months (DEB-TACE) versus 10.0 months (SEER) in AJCC II, p < 0.0001. Significant independent prognostic factors for OS were single primary tumor, no vascular invasion, normal α-fetoprotein and DEB-TACE. Conclusion: DEB-TACE in patients with unresectable AJCC stage I/II HCC was a significant independent prognostic factor for greater OS in a population-based study.

UR - http://www.scopus.com/inward/record.url?scp=84961837394&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961837394&partnerID=8YFLogxK

U2 - 10.2217/cer.15.54

DO - 10.2217/cer.15.54

M3 - Article

VL - 5

SP - 141

EP - 154

JO - Journal of Comparative Effectiveness Research

JF - Journal of Comparative Effectiveness Research

SN - 2042-6305

IS - 2

ER -